Diese Zusammenfassung enthält ausgewählte Informationen aus einer Originalpublikation und kann unter anderem bestimmte Interpretationen der publizierten Daten beinhalten. Für detaillierte Informationen wird deshalb auf die Originalpublikation verwiesen: Li G et al. Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. J Headache Pain 2023;24(1):129.¹

¹ Li G et al. Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. J Headache Pain 2023;24(1):129.
² Marmura MJ et al. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 2015;55(1):3–20.
³ Moher D et al. Preferred reporting items for systematic reviews and meta-analysis. the PRISMA statement. PLoS 2009;Med6(7):e1000097.
⁴ Lipton RB et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 2023;22(3):209–217.
⁵ Croop R et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 2022;62(9): 1153–1163.
⁶ Lipton RB et al. DFN-02 (Sumatriptan 10 mg with a permeation enhancer) nasal spray vs placebo in the Acute treatment of migraine: a Double-Blind, placebo-controlled study. Headache 2018;58(5):676–687
⁷ Rao AS et al. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine. Headache 2016;56(2):331–340.
⁸ Cady RK et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (the TARGET study). Headache 2015;55(1):88–100.
⁹ Pfaffenrath V et al. Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia 2012;32(10):766–777.
¹⁰ Aurora SK et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 2011;51(4):507–517.
¹¹ Djupesland PG and Docekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 2010;30(8):933–942.
¹² Aurora SK et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009;49(6):826–837.
¹³ Wang SJ et al. Intranasal sumatriptan study with high placebo response in taiwanese patients with migraine. J Chin Med Assoc 2007;70(2):39–46.
¹⁴ Dodick D et al. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 2005;19(2):125–136.
¹⁵ Gawel M et al. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine–results from phase 1 of the REALIZE Study. Headache 2005;45(1):7–16.
¹⁶ Charlesworth BR et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebocontrolled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003;17(9):653–667.
¹⁷ Peikert A et al. Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. Eur J Neurol 1999;6(1):43–49.
¹⁸ Diamond S et al. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 1998;7(3):234–240.
¹⁹ Ryan R et al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 1997;49(5):1225–1230.
²⁰ Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53(12):1285–1291
²¹ Hoffert MJ et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995;35(2):65–69.
²² Salonen R et al. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol 1994;241(8):463–469.

Fachpersonen können bei Grünenthal eine vollständige Kopie der zitierten Referenzen anfordern.

Wirksamkeit und Sicherheit von intranasalen Wirkstoffen für die akute Behandlung von Migräne